How should I manage an amoxicillin‑induced rash?

Management of Amoxicillin-Induced Rash

Discontinue amoxicillin immediately and provide symptomatic treatment with oral antihistamines and topical corticosteroids; do not label the patient as penicillin-allergic unless high-risk features are present. 1, 2

Immediate Risk Stratification

High-risk features requiring emergency transfer:

• Blistering, skin detachment, or mucosal involvement (eyes, mouth, genitals) suggesting Stevens-Johnson syndrome or toxic epidermal necrolysis 1, 3
• Angioedema, respiratory compromise, or cardiovascular instability indicating anaphylaxis 3
• Fever with systemic symptoms, lymphadenopathy, or eosinophilia suggesting DRESS syndrome 3

Low-risk presentation (suitable for outpatient management):

• Isolated maculopapular (morbilliform) rash appearing days after starting amoxicillin without systemic symptoms 1, 2
• Urticaria without angioedema or respiratory symptoms 1

Immediate Management of Low-Risk Rash

Stop amoxicillin immediately – continuing the antibiotic provides no benefit and may worsen the rash, particularly if the original indication was a viral infection. 1, 2

Symptomatic treatment:

• Oral antihistamines (e.g., cetirizine, loratadine) for pruritus 2
• Topical corticosteroids for localized inflammation 2
• Acetaminophen or ibuprofen for fever or discomfort 1, 2
• Monitor for progression over 24–48 hours 1

Special Consideration: Infectious Mononucleosis

Patients with infectious mononucleosis have a 30–100% chance of developing a non-pruritic morbilliform rash when given amoxicillin, which represents a unique virus-drug interaction rather than a true penicillin allergy. 1, 3

• This rash does not indicate true penicillin allergy and should not result in permanent penicillin-allergy labeling 1, 3
• Patients can typically take penicillins safely after the EBV infection resolves 1
• If bacterial infection requires continued treatment, switch to a non-beta-lactam antibiotic such as a macrolide 1
• Amoxicillin should not be administered to patients with known mononucleosis 3

Documentation and Allergy Labeling

Do NOT label as penicillin-allergic when:

• The reaction is an isolated maculopapular rash without systemic signs 1, 2
• The rash occurred during a viral illness (especially EBV, upper respiratory infection) 1
• There are only gastrointestinal symptoms (nausea, vomiting, diarrhea) 1
• No clear temporal relationship exists between drug exposure and symptoms 1
• The patient has continued amoxicillin use without reaction 1

The allergy label can be removed without testing when:

• The reaction was non-severe, confined to skin, and occurred in remote childhood 1
• Non-severe delayed rash occurred more than one year ago 1
• The patient cannot recall details of the reaction 1

Provide written confirmation that the patient is not penicillin-allergic and instruct removal of the allergy label from electronic health records, pharmacy systems, and outpatient charts. 1

Future Antibiotic Use and Re-exposure Strategy

For non-severe delayed rash occurring > 1 year ago:

• Perform a direct supervised oral amoxicillin challenge (single dose under observation) without prior skin testing when antibiotics are next needed 1, 2
• Approximately 93–94% of patients tolerate this challenge without reaction 1
• Over 90% of children with reported amoxicillin rashes tolerate the drug on re-exposure 1

For non-severe delayed rash occurring < 1 year ago:

• Avoid amoxicillin until a year has passed 1
• Consider alternative β-lactams with dissimilar side chains: cefdinir, cefuroxime, cefpodoxime, or ceftriaxone 1
• Avoid cephalosporins sharing the same R1 side chain as amoxicillin (cephalexin, cefaclor, cefamandole) 1

For immediate-type reactions (urticaria within ≤ 1 hour):

• If the reaction occurred > 5 years ago and was non-severe, a therapeutic dose may be administered in a controlled setting 1
• If the reaction occurred ≤ 5 years ago or was severe, refer for formal allergy work-up before any re-exposure 1, 2

Permanent Avoidance Scenarios

Anaphylaxis:

• Permanently avoid all penicillins and refer to an allergist 1, 2

Severe cutaneous adverse reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS):

• Permanently avoid all β-lactams 1, 2
• Permanently avoid penicillins and first-/second-generation cephalosporins 1, 2

Cross-Reactivity with Other β-Lactams

• True cephalosporin cross-reactivity with penicillins is 0.1–2%, not the historic 10% 1
• Cross-reactivity is driven by R1 side-chain similarity, not the β-lactam ring 1
• Second- and third-generation cephalosporins with dissimilar side chains can be used safely in non-severe penicillin allergy 1
• Cephalosporins must not be used in immediate-type (anaphylactic) penicillin reactions 1
• Carbapenems exhibit negligible cross-reactivity with penicillins 1
• Aztreonam has no cross-reactivity with penicillins, except when used with ceftazidime or cefiderocol (shared side chain) 1

Role of Penicillin Skin Testing

Do NOT perform penicillin skin testing for:

• Delayed maculopapular rashes (low sensitivity and specificity) 1, 2
• Non-severe reactions that occurred > 1 year ago (proceed directly to oral challenge) 1
• Non-IgE-mediated reactions 1

Skin testing has limited utility because:

• Sensitivity decreases over time since the reaction 1
• Positive predictive value is less than 50% 1
• It does not predict delayed-type reactions 1

Public Health Impact of Inappropriate Labeling

Mislabeling patients as penicillin-allergic leads to:

• Increased use of broad-spectrum agents (vancomycin, fluoroquinolones) 1
• Higher rates of antimicrobial resistance (MRSA, VRE) 1
• Greater healthcare costs and longer hospital stays 1
• Suboptimal clinical outcomes 1

True penicillin allergy prevalence:

• Formal testing confirms genuine penicillin allergy in only 1.6%–6% of individuals with a reported reaction 1

Common Pitfalls to Avoid

• Do not continue amoxicillin "to complete the course" when the original indication was a viral infection 1
• Do not switch to macrolides or other antibiotics solely because a rash developed during a viral illness 1
• Do not assume every rash during antibiotic therapy represents true drug allergy; many are virus-drug interactions 1
• Do not rely on the outdated 10% cephalosporin cross-reactivity figure; the accurate rate is 0.1–2% 1
• Do not perform penicillin skin testing for delayed maculopapular rashes 1